VKTX has been the subject of a number of other research reports. Raymond James upgraded Viking Therapeutics from an outperform rating to a strong-buy rating and set a $43.00 price objective for the company in a research report on Monday, November 19th. They noted that the move was a valuation call. B. Riley assumed coverage on Viking Therapeutics in a research report on Tuesday, December 11th. They issued a buy rating and a $16.00 price objective for the company. BidaskClub upgraded Viking Therapeutics from a strong sell rating to a sell rating in a research report on Wednesday, January 2nd. Svb Leerink assumed coverage on Viking Therapeutics in a research report on Friday, February 22nd. They issued a mkt perform rating for the company. Finally, Leerink Swann assumed coverage on Viking Therapeutics in a research report on Friday, February 22nd. They issued a market perform rating and a $10.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $22.88.
NASDAQ:VKTX traded up $0.06 during mid-day trading on Thursday, hitting $7.78. 1,233,025 shares of the company’s stock traded hands, compared to its average volume of 2,875,690. Viking Therapeutics has a 12 month low of $3.69 and a 12 month high of $24.00. The company has a market cap of $570.25 million, a price-to-earnings ratio of -9.85 and a beta of 2.73.
Several hedge funds have recently made changes to their positions in the business. FMR LLC acquired a new position in shares of Viking Therapeutics in the 3rd quarter worth approximately $125,858,000. Fiera Capital Corp bought a new position in shares of Viking Therapeutics in the 4th quarter worth $11,167,000. BlackRock Inc. boosted its position in shares of Viking Therapeutics by 22.4% in the 4th quarter. BlackRock Inc. now owns 4,099,406 shares of the biotechnology company’s stock worth $31,361,000 after purchasing an additional 749,505 shares during the last quarter. Jennison Associates LLC bought a new position in shares of Viking Therapeutics in the 3rd quarter worth $9,501,000. Finally, Vanguard Group Inc boosted its position in shares of Viking Therapeutics by 21.4% in the 3rd quarter. Vanguard Group Inc now owns 2,877,287 shares of the biotechnology company’s stock worth $50,123,000 after purchasing an additional 508,097 shares during the last quarter. Institutional investors own 65.69% of the company’s stock.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
Further Reading: Mutual Funds
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.